The Clorox Company $CLX Shares Acquired by Confluence Investment Management LLC

Confluence Investment Management LLC lifted its stake in The Clorox Company (NYSE:CLX) by 12.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 941,510 shares of the company’s stock after purchasing an additional 100,764 shares during the quarter. Clorox comprises about 1.6% of Confluence Investment Management LLC’s holdings, making the stock its 24th largest holding. Confluence Investment Management LLC owned 0.76% of Clorox worth $113,047,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CLX. Wood Tarver Financial Group LLC acquired a new stake in shares of Clorox in the fourth quarter valued at approximately $31,000. Ransom Advisory Ltd acquired a new stake in shares of Clorox in the first quarter valued at approximately $35,000. GW&K Investment Management LLC increased its holdings in shares of Clorox by 239.1% in the first quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock valued at $43,000 after purchasing an additional 208 shares during the last quarter. Roble Belko & Company Inc increased its holdings in shares of Clorox by 140.7% in the first quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock valued at $53,000 after purchasing an additional 211 shares during the last quarter. Finally, IMA Advisory Services Inc. acquired a new stake in shares of Clorox in the first quarter valued at approximately $58,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Trading Down 0.5%

NYSE:CLX opened at $123.75 on Friday. The firm has a market cap of $15.14 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 1.00 and a beta of 0.52. The stock has a fifty day moving average price of $124.27 and a 200 day moving average price of $132.44. The Clorox Company has a 12-month low of $116.53 and a 12-month high of $171.37. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same period last year, the firm earned $1.82 earnings per share. Clorox’s quarterly revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Sell-side analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Wednesday, August 13th were paid a $1.24 dividend. This is a boost from Clorox’s previous quarterly dividend of $1.22. This represents a $4.96 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date was Wednesday, August 13th. Clorox’s payout ratio is 76.07%.

Insiders Place Their Bets

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares in the company, valued at $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CLX has been the subject of several analyst reports. Citigroup reiterated a “neutral” rating and issued a $135.00 price objective (down from $140.00) on shares of Clorox in a research report on Tuesday, July 15th. UBS Group lowered their price objective on Clorox from $150.00 to $134.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. Barclays lowered their price objective on Clorox from $129.00 to $119.00 and set an “underweight” rating for the company in a research report on Tuesday, July 15th. Wells Fargo & Company lowered their price objective on Clorox from $138.00 to $130.00 and set an “equal weight” rating for the company in a research report on Friday, September 5th. Finally, Jefferies Financial Group lowered their price target on Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Clorox presently has a consensus rating of “Reduce” and an average target price of $142.18.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.